|Other names||Non-invasive positive pressure ventilation (NIPPV), NIV, NPPV|
Non-invasive ventilation (NIV) is the use of breathing support administered through a face mask, nasal mask, or a helmet. Air, usually with added oxygen, is given through the mask under positive pressure; generally the amount of pressure is alternated depending on whether someone is breathing in or out. It is termed "non-invasive" because it is delivered with a mask that is tightly fitted to the face or around the head, but without a need for tracheal intubation (a tube through the mouth into the windpipe). While there are similarities with regard to the interface, NIV is not the same as continuous positive airway pressure (CPAP), which applies a single level of positive airway pressure throughout the whole respiratory cycle; CPAP does not deliver ventilation but is occasionally used in conditions also treated with NIV.
Non-invasive ventilation is used in acute respiratory failure caused by a number of medical conditions, most prominently chronic obstructive pulmonary disease (COPD); numerous studies have shown that appropriate use of NIV reduces the need for invasive ventilation and its complications. Furthermore, it may be used on a long-term basis in people who cannot breathe independently as a result of a chronic condition.
NIV for acute respiratory failure is used particularly for severe exacerbations of chronic obstructive pulmonary disease (COPD) but also for acute decompensated heart failure and other acute conditions. NIV can be used acutely and long-term. In some people who have presented with acute respiratory failure, there is an ongoing need for long-term use of NIV at home.
Non-invasive ventilation has been suggested in the treatment for coronavirus disease 2019 (COVID-19) where shortages of invasive ventilation equipment and facilities may arise. The risk of poorly fitting masks emitting aerosols can require full protection gear for caregivers.
The most common indication for acute non-invasive ventilation is for acute exacerbation of chronic obstructive pulmonary disease. The decision to commence NIV, usually in the emergency department, depends on the initial response to medication (bronchodilators given by nebulizer) and the results of arterial blood gas tests. If after medical therapy the lungs remain unable to clear carbon dioxide from the bloodstream (respiratory acidosis), NIV may be indicated. Many people with COPD have chronically elevated CO2 levels with metabolic compensation, but NIV is only indicated if the CO2 is acutely increased to the point that the acidity levels of the blood are increased (pH<7.35). There is no level of acidity above which NIV cannot be started, but more severe acidosis carries a higher risk that NIV alone is not effective and that mechanical ventilation will be required instead.
Other causes of AHRF
Bronchiectasis may lead to acute hypercapnic respiratory failure (AHRF), and NIV may be used similarly as for COPD. This is particularly the case where the underlying cause is cystic fibrosis. Cystic fibrosis also causes high volumes of sputum (phlegm) which may require specialised physiotherapy assistance and sometimes the insertion of a mini-tracheostomy to clear this.
In people with chest wall deformity or neuromuscular disease, NIV may be commenced if the CO2 level is elevated even if it has not yet caused acidosis. In neuromuscular disease, a breathing measurement known as the vital capacity is used to determine a need for breathing support.
Obesity hypoventilation syndrome (OHS) may cause acute hypercapnic respiratory failure. When this is the case, the criteria for commencing acute NIV are similar to those for COPD (decreased pH, elevated CO2), although there are some scenarios where NIV may be initiated in hospitalized people despite a normal pH; these include people with daytime somnolence, sleep-disordered breathing and/or evidence of right ventricle heart failure.
In acute cardiogenic pulmonary oedema caused by decompensated heart failure, the quality of evidence is poor but studies have shown a reduced risk of death and a decreased need for tracheal intubation for both NIV and CPAP. Both CPAP and NIV may be used in the prehospital care setting.
Acute severe asthma may cause AHRF, when it is labelled "near-fatal asthma". There is limited evidence on whether NIV is effective in this situation, which carries a high risk of requiring mechanical ventilation. Professional guidelines therefore do not give a clear recommendation, and it is suggested that NIV is only used in an intensive care unit setting where further deterioration can be managed immediately, or not at all. Some people with chronic asthma develop fixed airways disease that resembles COPD, and NIV may be used in that setting.
Respiratory failure may develop after major surgery. NIV may be used in this setting during the recovery period. In those who have undergone mechanical ventilation on the intensive care unit and are considered at high risk of recurrence, NIV may be used to prevent this. However, if respiratory failure does develop, recommencement of mechanical ventilation is recommended over NIV to treat this. In those who were ventilated for hypercapnic respiratory failure, NIV may be used to facilitate the weaning process.
Chronic use of NIV ("home NIV") may be indicated for severe COPD. A review from 2021 demonstrated that the chronic use of non-invasive ventilation improves daytime hypercapnia. In addition, in stable chronic obstructive pulmonary disease, survival seems to be improved and there might be a short term benefit of health-related quality of life.
Home NIV may also be indicated in people with neuromuscular disease and chest wall deformity.
People with obesity hypoventilation syndrome often require NIV initially in their care, but many can be switched to CPAP. American Thoracic Society (ATS) clinical practice guidelines recommend that NIV is provided on discharge with a further sleep study assessment as an outpatient. With regards to initiation of positive pressure treatment, the ATS guidelines recommend that in people being investigated for possible obstructive sleep apnea (OSA, a related condition), measurement of arterial carbon dioxide (in high probability) or venous bicarbonate (in moderate probability) is performed to identify OHS and to determine an indication for treatment. In those with both severe OSA and OHS, initial treatment with CPAP is recommended although the quality of research supporting this over NIV is poor. In the 30% of people with OHS who do not also have severe OSA, NIV may be more effective but is also more cost- and resource-intensive. In those who have both OSA and OHS, poor response to CPAP despite good adherence may be an indication to switch to NIV.
People with motor neuron disease (MND) may require home NIV in the course of their illness. Guidelines in the United Kingdom stipulate that assessment of respiratory function is part of the multidisciplinary management of MND.
A number of terms have been used in the medical literature to describe NIV. The more formal name "non-invasive positive pressure ventilation" (NPPV or NIPPV) has been used to distinguish it from the use of the now very rare negative pressure ventilator ("iron lung"). The brand name BiPAP/BIPAP (for Bilevel Positive Airway Pressure) has also enjoyed a degree of popularity, after an early NIV machine produced by Respironics, but its use is now discouraged.
Non-invasive ventilation has been used since 1940s for various indications, but its present-day use for chronic breathing problems arose in the 1980s for people with chronic respiratory muscle weakness, and in the 1990s on intensive care units and other acute care settings for acute respiratory failure.
Since 2000 acute NIV has been used widely in the treatment of acute respiratory failure, particularly in people with COPD, including on general wards rather than the intensive care unit setting. In the United Kingdom, a 2017 report by NCEPOD found that there were widespread problems in the delivery of high-quality care to patients.
- Hörmann C, Baum M, Putensen C, Mutz NJ, Benzer H (January 1994). "Biphasic positive airway pressure (BIPAP)--a new mode of ventilatory support". European Journal of Anaesthesiology. 11 (1): 37–42. PMID 8143712.
- Davidson AC, Banham S, Elliott M, Kennedy D, Gelder C, Glossop A, et al. (April 2016). "BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults". Thorax. 71 (Suppl 2): ii1–i35. doi:10.1136/thoraxjnl-2015-208209. PMID 26976648.
- Nava S, Hill N (July 2009). "Non-invasive ventilation in acute respiratory failure". Lancet. 374 (9685): 250–259. doi:10.1016/S0140-6736(09)60496-7. PMC 7138083. PMID 19616722.
- Forrest IS, Jaladanki SK, Paranjpe I, Glicksberg BS, Nadkarni GN, Do R (October 2021). "Non-invasive ventilation versus mechanical ventilation in hypoxemic patients with COVID-19". Infection. 49 (5): 989–997. doi:10.1007/s15010-021-01633-6. PMC 8179090. PMID 34089483.
- Murthy S, Gomersall CD, Fowler RA (April 2020). "Care for Critically Ill Patients With COVID-19". JAMA. 323 (15): 1499–1500. doi:10.1001/jama.2020.3633. PMID 32159735.
- Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. (August 2017). "Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure". The European Respiratory Journal. 50 (2): 1602426. doi:10.1183/13993003.02426-2016. PMID 28860265.
- Berbenetz N, Wang Y, Brown J, Godfrey C, Ahmad M, Vital FM, Lambiase P, Banerjee A, Bakhai A, Chong M (April 2019). "Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema". The Cochrane Database of Systematic Reviews. 2019 (4): CD005351. doi:10.1002/14651858.CD005351.pub4. PMC 6449889. PMID 30950507.
- "SIGN guideline 158: British guideline on the management of asthma". Scottish Intercollegiate Guideline Network (SIGN). BTS/SIGN. Retrieved 15 August 2019.
- Arnal JM, Texereau J, Garnero A (August 2017). "Practical Insight to Monitor Home NIV in COPD Patients". Copd. 14 (4): 401–410. doi:10.1080/15412555.2017.1298583. PMID 28339316. S2CID 205888171.
- Raveling T, Vonk J, Struik FM, Goldstein R, Kerstjens HA, Wijkstra PJ, Duiverman ML (August 2021). "Chronic non-invasive ventilation for chronic obstructive pulmonary disease". The Cochrane Database of Systematic Reviews. 2021 (8): CD002878. doi:10.1002/14651858.cd002878.pub3. PMC 8407093. PMID 34368950.
- Mokhlesi B, Masa JF, Brozek JL, Gurubhagavatula I, Murphy PB, Piper AJ, et al. (August 2019). "Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline". American Journal of Respiratory and Critical Care Medicine. 200 (3): e6–e24. doi:10.1164/rccm.201905-1071ST. PMC 6680300. PMID 31368798.
- Masa JF, Pépin JL, Borel JC, Mokhlesi B, Murphy PB, Sánchez-Quiroga MÁ (March 2019). "Obesity hypoventilation syndrome". European Respiratory Review. 28 (151): 180097. doi:10.1183/16000617.0097-2018. PMC 9491327. PMID 30872398.
- Guideline Development Group (February 2016). "Motor neurone disease: assessment and management". National Institute for Health and Clinical Excellence. NICE. Retrieved 19 July 2017.
- Pierson DJ (January 2009). "History and epidemiology of noninvasive ventilation in the acute-care setting". Respiratory Care. 54 (1): 40–52. PMID 19111105.
- Rittayamai, N; Grieco, DL; Brochard, L (September 2022). "Noninvasive respiratory support in intensive care medicine". Intensive Care Medicine. 48 (9): 1211–1214. doi:10.1007/s00134-022-06762-6. PMC 9244137. PMID 35759009.
- Juniper MC, Ellis G, Protopapa KL, Smith N (September 2017). "Inspiring Change: a report on acute non-invasive ventilation". British Journal of Hospital Medicine. London, England. 78 (9): 497–502. doi:10.12968/hmed.2017.78.9.497. PMID 28898156.